Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment of patients with previously untreated non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. Efficacy of afatinib in EGFR tyrosine kinase inhibitor-naïve (TKI-naïve) patients with uncommon EGFR mutations (other than exon 19 deletions or exon 21 point mutations) has been reported; however, efficacy in TKI-pretreated patients with uncommon EGFR mutations is unknown. Materials and Methods. In the afatinib compassionate use program (CUP), patients with advanced or metastatic, histologically confirmed NSCLC progressing after at least one line of chemotherapy and one line of EGFR-TKI treatment were enrolled. Demographic data, mutation type, response rates, time to treatment failure (TTF), and safety in patients harboring uncommon EGFR mutations were reported.
INTRODUCTION
Treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is standard in patients with metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations.The two most common EGFR mutations account for ∼90% of all mutation-positive NSCLC cases and are known to confer sensitivity to EGFR-TKIs: in-frame deletions in exon 19 (Del19) and a point mutation in exon 21 (L858R) [1] .The efficacyof first-generation reversible EGFR-TKIs like erlotinib and gefitinib on tumors with uncommon EGFR mutations was reported to be lower than in common mutations [2, 3] .
Afatinib is an orally available ErbB family blocker, binding to ErbB1 (EGFR), ErbB2 (HER2) and ErbB4, and inhibiting signaling of all homodimers and heterodimers of these receptors [4, 5] . Due to the acrylamide group in the molecule, the binding is-in contrast to gefitinib and erlotinib-covalent and thus irreversible. Afatinib has shown superior progression-free survival (PFS), overall survival (OS), and patient-reported outcomes compared with standard chemotherapy as first-line treatment of patients with NSCLC harboring common EGFR mutations [6] [7] [8] [9] . In preclinical models, afatinib has also shown activity against uncommon EGFR mutations like T790M, which has been associated with acquired resistance to EGFR-TKIs [5, 10] . Treatment options for patients with acquired resistance to gefitinib and erlotinib [11] are urgently needed.
To investigate the efficacy and tolerability of afatinib in heavily pretreated patients with uncommon EGFR mutations, a subgroup of appropriate patients enrolled in a compassionate use program (CUP) were selected and analyzed.The results of the whole CUP cohort are published elsewhere [12] .
MATERIALS AND METHODS

Compassionate Use Program
The CUP was started in May 2010 to enable access to afatinib for patients with life-threatening disease and no other standard treatment option.Inclusioncriteria for theCUP werebased on the LUX-Lung 1 study comparing afatinib monotherapy with placebo in heavily pretreated patients. LUX-Lung 1 failed to reach its primary endpoint of improving OS but resulted in a doubling of PFS [13] . Patients enrolled in the CUP had advanced NSCLC and were ineligible to participate in another actively accruing afatinib phase III trial, had failed at least one line of cytotoxic chemotherapy, and showed tumor progression after clinical benefit on erlotinib or gefitinib (i.e., stable disease for $6 months, a complete response, or partial response) or the presence of an activating mutation of the EGF/Her receptor family, were aged $18 years, had no further established treatment option available, and had provided written informed consent.The competent authorities (Federal Institute for Drugs and Medical Devices [BfArm]; goverments' steering committee) were informed, and approval by the ethics committee was given (837.105. 10[7114] ). The CUP was stopped with market availability of afatinib in the European Medicines Agency region.
Centers and Clinical Data
In total, 573 patients were enrolled from 118 centers in Germany, and 546 were treated with afatinib. Physicians were asked to provide age, sex, pretreatments, comorbidities, and mutational status to allow checks for eligibility and to report adverse events including tumor progression. All data were reported anonymously.
Physicians who had patients with uncommon mutations were approached after closure of the CUP by the authors to fill in a structured documentation sheet for more information on the mutational status (time of testing, EGFR detection method, response to reversible TKI and to afatinib).
Statistics
Descriptive analysis was performed for patient demographics. Time to treatment failure (TTF) was defined from start of afatinib treatment (if not reported, it was calculated as 7 days after shipment) to end of treatment (if not reported, the date of the last order was used). Significance was determined at p , .05. The database was locked on December 31, 2013, and patients still on treatment were censored. Survival curves were estimated using the Kaplan-Meier method for TTF. A Cox model was applied to estimate hazard ratios and 95% confidence intervals (CIs). Analyses were undertaken using MedCalc version 12.1.4.0 (MedCalc Software, Ostend, Belgium, https:// www.medcalc.org). Patients receiving ,2 months' targeted therapy before stopping due to progressive disease, death, or switching therapy were classified with a best response of "progressive disease," whereas patients who were on treatment .4 months were classified with a best response of "stable disease" if not reported differently.
RESULTS
Demographics of Patients With Uncommon EGFR Mutations
In total, 66 uncommon mutations in 60 patients were reported (18.4% of all known EGFR mutations in the CUP). Most patients (57%) received a reversible TKI in the second line, with a median treatment duration of 10.0 months (Tables 1, 2). The majority of patients (67%) received afatinib as third-or fourthline treatment, with median treatment duration of 3.6 months. Sixty-three percent were female, and the median age was 63 years, ranging from 30 to 84 years (Tables 1, 2 ). In some instances, cetuximab was added to afatinib in the course of treatment (n 5 6). Demographics of patients with uncommon EGFR mutations did not differ from the whole CUP population (Tables 1, 2) .
Uncommon EGFR Mutations
A total of 23 uncommon EGFR mutations were detected at time of diagnosis; 15 were reported to be acquired mutations (all T790M), and for the remaining cases, time of detection was not reported. Of the uncommon EGFR mutations detected, 21% were on exon 18, 9% were on exon 19, 55% were on exon 20, and 16% were on exon 21. A total of 30 patients (45% of uncommon mutations) had T790M mutations (18 had T790M plus exon 19, 11 had T790M plus exon 21, and 1 had T790M alone), 10 patients had G719X mutations (3 had G719A, 2 had G719C, 2 had G719S, 1 had G719A plus E709A, 1 had G719C plus E709A, and 1 had G719C plus L861Q), 6 had L861Q mutations (2 alone, 2 plus T790M and each one plus G719C or L858M), 4 had E709X mutations (3 had E709K plus L858R, 1 had E709A plus G719X), and 4 had insertions in exon 20 (1 also had Del19). Further mutations included A702S, A750V, deletion and insertion (delins) exon 19 (n 5 2), G753S, point mutation exon 19, S768I plus V769L, R776H plus L858R, L858M, L858M plus L861Q, G857E, and G861L plus T790M (Fig. 1 ). mutation (n 5 1) (p 5 .823). TTF for G719X (n 5 10) was 2.6 months (range: 0.2 to ongoing at 24.6 months); TTF for L861Q (n 5 4) was 3.3 months (range: 1.5-9.9 months); TTF for E709X (n 5 4) was 12.2 months (range: ongoing at 0.8-16.7 months); and TTF for insertion exon 20 (n 5 4) was 6.5 months (range: ongoing at 3.6-9.1 months). Patients with A702S, A750V, delins exon 19, G753S, point mutation exon 19, R776H, S768I, V769L, G857E, G861L, and L858M (n 5 14) had TTF varying from 0.8 to ongoing at 16.8 months. In total, 20 patients (33%) were still on treatment at time of database lock (Table 3) . Patients with common EGFR mutations (n 5 165) had a median TTF of 4.9 months (range: 0.1 to ongoing at 21.1 months), 4.6 months in patients with Del19 (n 5 106), and 5.8 months in L858R (n 5 59), compared with patients with uncommon mutations of 3.6 months (range: 0.2 to ongoing at 24.6 months) (Fig. 2) . This was not significant.
From 58 evaluable cases, 22% (n 5 13) had a partial response (including one mixed response), 47% (n 5 27) had stable disease, and 31% (n 5 18) had progressive disease as best response, with L858M mutations showing the highest percentage of patients with a partial response. T790M-mutated patients responded mostly with stable disease (56%) ( Table 4) .
Safety Profile
The complete safety profile from this CUP is reported elsewhere [12] . The afatinib safety profile was as expected, with diarrhea and skin-related adverse events being the most common; no new safety signals were observed. Afatinib was administered continuously at a starting dose of 50 mg in 38 patients (63%), 40 mg in 13 patients (22%), and 30 mg in 9 patients (15%). Dose reductions from 50 to 40 mg were observed in 19 patients and to 30 mg in 10 patients.
DISCUSSION
To the knowledge of the authors, this study has the largest prospective cohort of patients carrying uncommon EGFR mutations and failing on EGFR-TKI published so far; however, the intention of the CUP was to provide a treatment option for patients for whom no further established therapy was available. Consequently, only a minimal data set was required for inclusion, no structured data collection was rolled out, and no source data verification was performed, limiting the quality and generalizability of the data. The reported incidence of 11% of nonacquired uncommon EGFR mutations is in line with other reports [6, 7, 14, 15] . The data reported so far regarding distribution of uncommon mutations are either from TKI-naïve or mixed populations; therefore, a comparison with this population is not possible. Beau-Faller et al. reported an incidence in TKI-naïve patients of 40% for insertions in exon 20 (ins exon 20) but only 12% complex mutations [14] . Our cohort consists of 63% complex mutations but only 5% ins exon 20, indicating that although complex mutations are acquired during reversible EGFR-TKI treatment, patients with tumors harboring the ins exon 20 mutation were unlikely to be treated in later lines. Yasuda et al. described that the structure of ins exon 20 activates EGFR without increasing its affinity for EGFR-TKIs [16] ; however, a certain ins exon 20 mutation (Y764insFQEA) was described to be highly sensitive to EGFR-TKIs in vitro, and patients with NSCLC harboring this mutation responded to erlotinib. Because we do not have detailed information on the specific ins exon 20 mutation included in our cohort, we can only speculate whether the observed outcome (TTF 6.5 months) might be due to higher incidence of this responding insertion mutation. In our analysis, afatinib has generally shown efficacy in patients with uncommon EGFR mutations but to a lesser degree compared with patients with common EGFR mutations (3.8 and 5.1 months, respectively). Nonetheless, uncommon mutations were a very heterogeneous group, with E709X mutations and rare mutations on exon19 showing quite a long time to treatment failure (.12 and 6.5 months, respectively) and good response rates, whereas G719X mutations showed less benefit (2.6 months).
Only limited data are available on efficacy of reversible EGFR-TKIs on uncommon EGFR mutations, and these data are mostly for TKI-naïve patients. Klughammer et al. reported a TTF of 3.5 months for uncommon EGFR mutations from several trials with erlotinib in TKI-naïve patients [17] . Wu et al., excluding de novo T790M and ins exon 20, showed a median PFS of 5.0 months in TKI-naïve patients treated with reversible EGFR-TKIs, driven mainly by G719X and X861X mutations (median PFS 6.0 months), whereas the other uncommon mutations progressed after 1.6 months [18] . In the large first-line studies comparing afatinib with chemotherapy, efficacy has also been reported in a broad variety of uncommon EGFR mutations. In this TKI-naïve cohort, however, de novo T790M and ins exon 20 mutations showed inferior results compared with other uncommon mutations with PFS of 2.9 months (95% CI: 1.2-8.3) for T790M, 2.7 months (95% CI: 1.8-4.2) for ins exon 20, and 10.7 months (95% CI: 5.6-14.7) for other uncommon mutations [19] .
G719X and ins exon 20 represent the largest subset in the heterogeneous group of uncommon EGFR mutations; in this subset, different patterns according to treatment line could be seen. In TKI-naïve patients, a median PFS of 1.4 months for ins exon 20 and 8.1 months for G719X have been reported [14] . Data from Wu et al. describing a PFS of 8.1 months for TKI-naïve patients with different stages of NSCLC harboring G719X mutations go into a similar direction [18] . A combined analysis [19] from LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 showed the same trend-although numerically higher-for afatinib in EGFR-TKI-naïve patients (2.7 months for ins exon 20 and 13.8 months for G719X). The different outcomes depending on EGFR-TKI experience and line of treatment could be interpreted as (a) positive selection of responding mutations (in the case of ins exon 20) and (b) potentially, a process of acquiring additional mutations that negatively affect outcomes. This could not be proven in this cohort because 50% of the patients with G719X mutations were tested for EGFR mutational status prior to treatment with reversible EGFR-TKI, and EGFR testing is unknown for the remaining patients.
T790M is a high-profile uncommon EGFR mutation. It can be detected de novo and is responsible for approximately 50% of acquired resistance to reversible EGFR-TKIs [10] due to the fact that these agents show in vitro halfmaximal inhibitory concentration values of roughly 250-fold higher for T790M [20] compared with common EGFR mutations, explaining their limited effectiveness. In vitro activity of afatinib on T790M mutations has been shown; however, clinical activity with afatinib monotherapy in patients after reversible EGFR-TKI failure did not meet expectations (PFS 3.3 vs. 1.1 months for placebo and no difference in OS) [13] . The different efficacy of afatinib in the TKI-naïve setting compared with patients with acquired resistance is in line with previously reported results in T790M-positive tumors, indicating that the predictive value of T790M in TKI response is dependent on the time point of the occurrence of the mutation. De novo T790M, together with an activating mutation, has been described by different authors, with an incidence ranging from #1% up to 65% [3, [21] [22] [23] [24] . These results were dependent on the sensitivity of the method, with more sensitive methods detecting a higher incidence of de novo T790M. If T790M is detected by conventional methods such as Sanger sequencing, the incidence is ∼1%. The largest series of patients with de novo T790M has been reported by Riely et al. Afatinib in Pretreated EGFR Mutant-Positive NSCLC [24] . The largest data set for acquired resistance was published by Oxnard et al. [27] . This group identified 58 patients with acquired TKI resistance by T790M and compared them with 35 patients with acquired TKI resistance without T790M. In this analysis,T790M conferred better survival and PFS than the lack of T790M, suggesting that T790M indicates a more indolent tumor when observed in the TKI-resistant setting [27] ; the data generated in the afatinib CUP program are consistent with these findings.
Third-generation EGFR-TKIs are under clinical development addressing T790M more or less exclusively. In phase I trials, AZD9291 and CO-1686 achieved response rates of 61% and 67%, respectively, in pretreated patients with acquired T790M mutations; response rates were 21% and 36%, respectively, in patients with T790M-negative tumors [28, 29] . Median PFS with AZD9291 and CO-1686, respectively, was 9.6 months and 10.4 months in patients with T790M-positive tumors and 2.8 months and 7.5 months in patients with T790M-negative disease [28, 29] .
Based on the current analyses, it seems that no clinical characteristic is associated with uncommon EGFR mutation. There were more male patients in the uncommon mutation group compared with those with common mutations, and a shorter time from initial diagnosis until enrollment for patients with L858R-mutated tumors compared with patients with tumors harboring Del19 mutations. Interestingly, patients with concomitant L858R-mutated tumors had similar treatment duration with afatinib as those with concomitant Del19-positive tumors. This is in contrast to the data from first-line trials in EGFR-mutated patients in which patients with L858R-positive tumors showed a shorter PFS [30] . An explanation could be that the acquired resistance mechanisms of L858R-positive tumors are distinct from those in Del19-positive tumors, rendering the former more prone to respond to afatinib. In this regard, it has been shown that L858R-positive tumors have low-level T790M clones at a higher incidence than Del19-positive tumors. In the analysis of the Korean group [26] , 75% of the de novo T790M were within the L858R group; however, only 25% were in the Del19 group.This is in line with Yu et al. [23] , who showed that de novo T790M mutations are ∼80% concurrent with L858R and only 20% coexistent with Del19 mutations. Whether this preference of T790M for L858R holds true in the acquired resistance setting is unclear. Data from Griesinger et al. do not indicate a difference in the incidence of acquired T790M between L858R-and Del19-positive disease [31] .
CONCLUSION
In summary, afatinib is clinically active in many TKIpretreated patients with NSCLC harboring uncommon EGFR mutations. Pronounced activity was observed with E709X mutations (TTF .12 months). In comparison with results reported in TKI-naïve patients, our data also indicate activity in patients with tumors carrying T790M and ins exon 20 mutations.
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